Worth reading
81Important
Scored from 3 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
19.9
% (year-on-year decline in revenue)Wording
Definitive
How definitive the wording is.Results for this period
Third quarter2023年4月1日〜2023年12月31日ConsolidatedJapanese GAAPNet Sales6,937¥ millionYear on year -19.9%
Operating profit-142¥ million
Ordinary income-70¥ million
Net income attributable to owners of the parent-3¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets14,269¥ million
of which net assets 11,055 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueFine Chemicals Business ¥2,462 million (YoY -19.3%), Flame Retardants Business ¥3,427 million (YoY -26.6%), Health Support Business ¥1,048 million (YoY +11.5%)
Segment profitFine Chemicals Business ¥359 million (YoY -19.1%), Flame Retardants Business ¥300 million (YoY -72.7%), Health Support Business ¥46 million (YoY +173.6%)
Outlook and shareholder returns
Revision to Earnings ForecastNo change
Factors Behind Changes in Business Performance
難燃剤事業における需要減少。ファインケミカル事業では電子材料製品市場の低迷と一部医薬関連製品の需要減少、難燃剤事業では販売数量・単価ともに下落した。
Disclosure regarding the going concern assumption
None.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥50 million / Extraordinary loss Loss on disposal of non-current assets ¥0 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年4月1日〜2023年12月31日 |
| Net Sales | ¥6,937 million (YoY -19.9%) |
| Operating profit | ¥-142 million |
| Ordinary income | ¥-70 million |
| Profit attributable to owners of the parent | ¥-3 million |
| Total assets | ¥14,269 million |
| Net assets | ¥11,055 million |
| Revision to Earnings Forecast | No change |
| Segment revenue | Fine Chemicals Business ¥2,462 million (YoY -19.3%), Flame Retardants Business ¥3,427 million (YoY -26.6%), Health Support Business ¥1,048 million (YoY +11.5%) |
| Segment profit | Fine Chemicals Business ¥359 million (YoY -19.1%), Flame Retardants Business ¥300 million (YoY -72.7%), Health Support Business ¥46 million (YoY +173.6%) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥50 million / Extraordinary loss Loss on disposal of non-current assets ¥0 million |
| Disclosure regarding the going concern assumption | None. |
| Factors Behind Changes in Business Performance | 難燃剤事業における需要減少。ファインケミカル事業では電子材料製品市場の低迷と一部医薬関連製品の需要減少、難燃剤事業では販売数量・単価ともに下落した。 |
Items this document does not state (22)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.難燃剤事業における需要減少の影響を受けたこと。加えて、ファインケミカル事業では電子材料製品市場の低迷と一部医薬関連製品の需要減少、難燃剤事業では国内外の市場環境悪化と販売数量・単価の下落があった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.